
Director, Commercial Operations EMEAI
Oxford Nanopore has developed a new generation of nanopore-based sensing technology for faster, information-rich, accessible and affordable molecular analysis. By enabling biological insights, we strive to improve life on Earth and beyond.
The Role:
Reporting to the VP Commercial EMEAI, this role partners with the Commercial leadership team to deliver operational excellence and commercial effectiveness within a life sciences organisation. You’ll drive an optimal regional E2E operating model, efficiencies, continuous improvement, strategic resourcing, and competency growth in commercial teams.
Act as the key link between customer-facing teams (Sales, Service & Support, Customer Care) and internal functions (Finance, IT, Product, Logistics, Supply Chain, Digital, Global Operations), translating strategy into scalable execution. Ensure commercial teams have compliant systems, high-quality data, and processes to drive sustainable growth, customer satisfaction, and long-term partnerships.
Responsibilities:
Customer Care Focus:
Other Responsibilities:
Qualifications:
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.

Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.